RESEARCH PAPER

Global Regulatory Pathways for Biologics: A Comparative Analysis of FDA, EMA, PMDA and CDSCO

Shivani Sharma[1*], Dr. Vijay bhalla[2]

[1*]Research Scholar, Department of Pharmacy, Shree Guru Gobind Singh Tricentenary University, Gurugram, Haryana. Email Id: pilanishivani@gmail.com

[2]Dean Industry collaborations and Internship Affairs, Shree Guru Gobind Singh Tricentenary University, Gurugram, Haryana. Email Id: vijay0434@gmail.com

Abstract

Background: Biologics represent a rapidly expanding class of therapeutic agents used in the management of autoimmune conditions, malignancies, rare diseases, and other complex medical disorders. Given their biological origin, structural intricacy, and inherent variability, biologics require regulatory frameworks that differ substantially from those applied to conventional small-molecule drugs. Although major regulatory authorities share common scientific principles, differences in regulatory processes and policy implementation continue to present challenges for global development.

Objective: This review aims to provide a comparative analysis of biologics regulatory pathways across four major international regulatory agencies: the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and the Central Drugs Standard Control Organization (CDSCO) in India.

Methods: A qualitative comparative assessment was conducted across key regulatory domains, including submission pathways, review procedures, chemistry, manufacturing and controls (CMC) requirements, nonclinical and clinical evidence expectations, expedited approval mechanisms, biosimilar frameworks, and post-approval pharmacovigilance obligations.

Results: The analysis reveals considerable convergence in scientific standards, particularly regarding manufacturing quality requirements, reliance on analytical characterization, and lifecycle management of biologics. Nevertheless, meaningful differences persist in areas such as accelerated approval pathways, interchangeability regulations, post-marketing requirements, and regulatory reliance mechanisms. Emerging markets are increasingly aligning with international principles while adapting standards to their local legal and healthcare contexts.

Conclusion: Despite notable progress in harmonizing biologics regulations globally, differences in legal frameworks, policies, and healthcare systems remain primary drivers of regulatory divergence. Strengthening international cooperation, broader adoption of WHO and ICH standards, and developing more adaptive regulatory frameworks will be essential to accelerating global biologics development and ensuring timely patient access to safe and effective treatments.

Keywords: Biologics, Global Regulatory Pathways, FDA, EMA, PMDA, CDSCO, Regulatory Harmonization, Chemistry Manufacturing and Controls (CMC), Pharmacovigilance

How to cite this article: Sharma S, Bhalla V. Global Regulatory Pathways for Biologics: A Comparative Analysis of FDA, EMA, PMDA and CDSCO. Int J Drug Deliv Technol. 2026;16(69s): 1816-1832. DOI: 10.25258/ijddt.16.69s.180

Graphical Abstract



1. Introduction

Biologics differ fundamentally from conventional small-molecule drugs in their chemical complexity, biological origin, and inherent variability characteristics that profoundly influence every stage of their development, manufacture, regulation, and clinical use [1]. Small-molecule drugs are typically produced through well-defined chemical processes, yielding compounds of relatively low molecular weight that can be fully characterized and reliably reproduced. Biologics, by contrast encompass a broad range of products including monoclonal antibodies, recombinant proteins, vaccines, and cell- and gene-based therapies that are derived from living systems such as bacteria, yeast, or mammalian

*Author for Correspondence: pilanishivani@gmail.com

cells. These products are large three-dimensional macromolecules whose biological activity depends on precise folding patterns post-translational modifications, and structural features that cannot always be fully resolved even with the most advanced analytical technologies available today [2].

A distinguishing feature of biologics is their reliance on living biological systems for production which introduces variability that has no real equivalent in conventional chemical synthesis. In the biologics field the principle that "the process is the product" holds particular significance: even minor changes to cell lines, growth conditions, raw materials, or purification procedures can produce meaningful differences in the final product. Factors such as temperature fluctuations, pH shifts, changes in nutrient composition, or variations in fermentation duration can all affect protein expression, folding, glycosylation patterns, and impurity profiles. These seemingly small modifications may, in turn, influence a biologic's stability, pharmacokinetics, immunogenicity, and clinical performance. Achieving and maintaining batch-to-batch consistency is therefore one of the most demanding scientific and regulatory challenges in biologics development and manufacturing [3].

The inherent variability of biologics has profound implications for analytical characterization and quality control. While small-molecule drugs can often be comprehensively characterized using standard physicochemical methods, biologics require a broad panel of orthogonal analytical techniques to assess key quality attributes such as primary amino acid sequence, higher-order structure, post-translational modifications, biological activity, and impurity profiles. Even with significant advances in analytical science, complete structural characterization of a biologic product is seldom achievable. As a result, regulatory authorities place considerable emphasis on controlling the manufacturing process itself to ensure it remains robust and reproducible throughout the product's lifecycle. This process-centric philosophy is a defining feature of biologics regulation and reflects the intrinsic connection between manufacturing conditions and product quality [4].

Immunogenicity represents another critical distinction between biologics and small-molecule drugs. As large, protein-based molecules, biologics can be recognized by the immune system as foreign, potentially triggering immunological responses that reduce therapeutic efficacy or cause adverse effects. Several factors can influence immunogenicity, including protein aggregation, the presence of impurities, changes in formulation, and the route of administration risks that are generally lower with small-molecule compounds. Because of this immunogenic potential, preclinical and clinical studies must be carefully designed to evaluate immune responses, and robust post-marketing surveillance is essential to track long-term safety outcomes. This reality further underscores the need for specialized regulatory frameworks tailored to the unique risk profile of biologic products [5].

The clinical development and lifecycle management of biologics are equally shaped by their complexity and variability. Clinical programs for biologics must account for factors such as mechanism of action, target specificity, and patient population heterogeneity considerations that often differ substantially from those relevant to small-molecule therapies. Moreover, modifications to the manufacturing process such as scale-up, site transfers, or process optimization are frequently unavoidable during a product's commercial lifetime. For biologics, any such changes require thorough comparability studies to demonstrate that the quality, safety, and efficacy of the post-change product remain equivalent to those of the pre-change version. This requirement for analytical comparability, rather than simple chemical equivalence, further distinguishes biologics from small-molecule drugs and adds a layer of regulatory complexity [6].

From a regulatory perspective, these fundamental differences have led all major international agencies to develop distinct approval pathways and evaluation criteria for biologics. While the core regulatory principles of quality, safety, and efficacy apply to all pharmaceutical products, biologics are subject to additional requirements relating to manufacturing controls, process validation, and post-approval change management. Agencies such as the FDA, EMA, PMDA, and CDSCO have each developed tailored guidelines and review procedures that reflect these specific considerations, emphasizing a holistic assessment of both the product and its manufacturing process rather than relying solely on end-product testing [7].

Figure 1. Regulatory Lifecycle of a Biologic Product



The global nature of biologics development adds yet another layer of complexity. Sponsors frequently seek to develop and register biologic products simultaneously across multiple jurisdictions, a goal that can be complicated by differences in regulatory requirements, data expectations, and review procedures. Some agencies may require region-specific data, additional risk management strategies, or local manufacturing controls. Navigating these divergent requirements while maintaining a consistent global product involves substantial scientific, operational, and regulatory challenges that are considerably less pronounced for small-molecule drugs, which benefit from a more harmonized international regulatory environment [8].

Table 1. Fundamental Differences Between Biologics and Small-Molecule Drugs

Parameter	Biologics	Small-Molecule Drugs	References
Molecular size	Large, high molecular weight macromolecules (e.g., proteins, antibodies, cells)	Small, low molecular weight chemical entities	9
Structural complexity	Highly complex, three-dimensional structures with folding and post-translational modifications	Simple, well-defined chemical structures	9,10
Source of production	Derived from living systems (bacteria, yeast, mammalian cells)	Chemically synthesized using defined reactions	10
Manufacturing process	Multistep biological processes; "process is the product"	Reproducible chemical synthesis	11
Batch-to-batch variability	Inherent variability due to biological systems	Minimal variability between batches	12
Structural characterization	Partial characterization using advanced analytical tools	Complete characterization possible	13
Immunogenicity risk	High potential for immune response	Generally low immunogenic risk	12,13
Regulatory emphasis	Strong focus on process control, CMC, and lifecycle management	Focus on end-product quality and bioequivalence	13

2. Regulatory Authorities and Scope

Biologic products are regulated by specialized national and regional authorities, each operating within distinct legal, scientific, and institutional frameworks. Although

these agencies differ in structure and jurisdiction, they share the common objective of ensuring that biologic medicines reaching patients meet robust standards of quality, safety, and efficacy. Given the complexity and inherent variability of biologics, regulatory oversight extends well beyond initial product review to encompass full lifecycle management, manufacturing process control, and ongoing post-marketing surveillance. Sponsors pursuing global biologics development must have a clear understanding of how each agency is structured and what falls within its regulatory mandate [14].

In the United States, the Food and Drug Administration (FDA) regulates biologics under both the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. The primary route for biologics approval is the Biologics License Application (BLA), which requires comprehensive evidence of product quality, nonclinical safety, and clinical efficacy. Regulatory oversight is shared between two centers: the Center for Drug Evaluation and Research (CDER), which has responsibility for many therapeutic proteins and monoclonal antibodies, and the Center for Biologics Evaluation and Research (CBER), which oversees vaccines, blood products, and certain cell and gene therapies. The FDA places strong emphasis on current Good Manufacturing Practices (cGMP), process validation, and inspection readiness, reflecting the importance of manufacturing consistency to biologic product quality. Following approval, the FDA enforces rigorous pharmacovigilance and risk management requirements to support ongoing safety monitoring [15].

The European Medicines Agency (EMA) administers the centralized Marketing Authorization Application (MAA) process, which serves as the primary route for biologic review and approval across the European Union. This centralized approach yields a single marketing authorization valid throughout all EU and European Economic Area member states, supporting regulatory harmonization and equitable patient access. Scientific evaluation is conducted by expert committees, most notably the Committee for Medicinal Products for Human Use (CHMP). The EMA's review framework places particular emphasis on quality-by-design principles, comparability assessments for manufacturing changes, and comprehensive risk management planning. The centralized structure also facilitates consistent post-marketing surveillance and coordinated regulatory decision-making across the region [15].

Figure 2. Organizational Framework of Major Regulatory Authorities for Biologics



In Japan, biologics regulation is a shared responsibility between the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW). The PMDA conducts detailed scientific evaluations of quality, nonclinical, and clinical data, while the MHLW holds final approval authority. A notable feature of Japan's regulatory system is its emphasis on proactive consultation meetings with sponsors throughout the development process. Japan has also established specialized pathways for advanced biologic products such as cell-based therapies and regenerative medicines, often involving conditional approvals and enhanced post-marketing obligations. These mechanisms reflect Japan's commitment to promoting therapeutic innovation while maintaining stringent patient safety standards [16].

In India, the Central Drugs Standard Control Organization (CDSCO) oversees biologics regulation in accordance with the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019. CDSCO is responsible for the approval of new biologic medicines, authorization of clinical studies, market

authorization, and the oversight of manufacturing and import licensing. India's biologics regulatory framework has evolved progressively in alignment with international standards established by bodies such as the International Council for Harmonisation (ICH) and the World Health Organization (WHO). Growing attention to clinical evidence generation, post-marketing surveillance, and thorough quality review reflects both India's rising importance as a global biologics manufacturing hub and its ongoing commitment to strengthening regulatory science [17].

Table 2. Regulatory Authorities and Scope of Biologics Oversight

Agency	Jurisdiction	Governing Legislation	Review Centers / Committees	Types of Biologics Regulated	Approval Scope	Post-Market Oversight	Reference
FDA	United States	PHS Act; FD&C Act	CDER, CBER	mAbs, vaccines, gene & cell therapies	National	REMS, PSURs	**18**
EMA	European Union	EU Pharmaceutical Legislation	CHMP, PRAC	Therapeutic proteins, vaccines, ATMPs	Centralized (EU-wide)	EU-RMP, EudraVigilance	**19**
PMDA	Japan	Pharmaceuticals and Medical Devices Act	PMDA + MHLW	Biologics, regenerative medicines	National	Re-examination system	**18**
CDSCO	India	Drugs & Cosmetics Act; NDCTR 2019	SECs, DCGI	Recombinant biologics, vaccines	National	PvPI, PSURs	**19,20**
WHO (Reference)	Global	WHO Technical Guidelines	Expert Committees	Prequalification biologics	Advisory	Global safety guidance	**20**
ICH (Harmonization)	Global	ICH Guidelines	Multiregional	Quality, safety, efficacy standards	Advisory	Guideline-based	**21**
Health Canada*	Canada	Food and Drugs Act	BGTD	Biologics & biosimilars	National	Pharmacovigilance	**22**

3. Submission Pathways and Review Processes

The submission pathways and regulatory review processes for biologics are designed to address the scientific complexity, manufacturing sensitivity, and clinical risk profile of these medicines. While all major regulatory authorities require comprehensive data demonstrating quality, safety, and efficacy, the specific procedures and structures for submission and review differ considerably across regions. These differences have practical implications for development strategies, approval timelines, and resource planning for sponsors seeking global market authorization.

In the United States, the FDA administers the BLA process for biologics approval. A BLA submission must include detailed CMC data, thorough nonclinical studies, and robust clinical trial evidence establishing the safety and efficacy of the product for its intended indication. Given that manufacturing is integral to biologic product quality, the FDA places strong emphasis on process validation, control of critical quality attributes, and compliance with current Good Manufacturing Practices (cGMP). The review process typically involves detailed dossier assessment, facility inspections, and interactive review cycles allowing sponsors to address queries or clarify data during evaluation. For products with significant public health implications or novel technologies, advisory committee consultations may also be convened [23].

In the European Union, the EMA's centralized MAA process provides a single scientific evaluation applicable to all EU and European Economic Area member states. The centralized review involves coordinated assessment by rapporteurs and co-rapporteurs drawn from national competent authorities, ensuring scientific rigor and consistency. The EMA's evaluation encompasses quality, nonclinical, and clinical data, with particular attention to manufacturing robustness, comparability evaluations, and risk management plans. This centralized structure streamlines regulatory approval and enables uniform post-marketing oversight across the region [24].

In Japan, the PMDA adopts an interactive, structured review approach that emphasizes early and sustained sponsor engagement. Pre-submission consultations are strongly encouraged to ensure that development plans align with regulatory requirements before formal

submission. Following the PMDA's systematic scientific evaluation of quality, nonclinical, and clinical data, the MHLW issues the final approval decision. Japan's review process frequently requires local clinical data or a well-justified rationale for extrapolating from international studies, reflecting a careful and patient-centered regulatory philosophy. Conditional approval decisions are often accompanied by enhanced post-marketing surveillance requirements [25].

Figure 3. Comparative Submission and Review Pathways for Biologics



In India, CDSCO evaluates biologics submissions through a national regulatory review process. Sponsors are required to submit comprehensive data packages covering quality, nonclinical, and clinical components, which are assessed by subject-specific expert committees. While CDSCO permits the use of foreign clinical data to support approval, such reliance must be substantiated by appropriate bridging studies or scientific justifications demonstrating the data's relevance to the Indian patient population. Regulatory review encompasses evaluation of manufacturing facilities, GMP compliance, and post-approval pharmacovigilance programs. India's regulatory framework continues to evolve, reflecting ongoing efforts to balance alignment with global standards and responsiveness to domestic public health needs [26].

Table 3. Comparative Submission Pathways and Review Processes for Biologics

Parameter	FDA	EMA	PMDA	CDSCO	Reference
Primary application	BLA	MAA	NDA/BA	New Drug Application	**27**
Review model	National	Centralized	National	National	**27**
Standard review timeline	~10–12 months	~210 active days	~12 months	Variable (12–18 months)	**28**
Priority review options	Fast Track, Breakthrough, RMAT	PRIME, CMA	Sakigake	Accelerated review (case-specific)	**28**
Advisory committee role	FDA Advisory Committees	CHMP experts	Expert panels	Subject Expert Committees	**29**
Pre-submission consultation	Type B/Type C meetings	Scientific advice	Formal consultation system	Pre-IND meetings	**30**
Local clinical data	Not always required	Generally not required	Often required	Bridge studies common	**31**
Facility inspection	Pre-approval inspections	Coordinated EU inspections	PMDA inspections	CDSCO inspections	**29**

4. Quality and Manufacturing (CMC) Requirements

Quality and manufacturing considerations form the cornerstone of regulatory assessment for biologic products, reflecting the fundamental relationship

between manufacturing processes and product quality. There is strong international consensus among agencies such as the FDA, EMA, PMDA, and CDSCO that thorough Chemistry, Manufacturing, and Controls (CMC) documentation is essential to ensuring the consistent quality, safety, and efficacy of biologics. Given the sensitivity of biologic molecules to manufacturing conditions, regulatory evaluation places considerable emphasis on process understanding, control strategies, and lifecycle management [32].

Demonstrating process consistency is one of the central objectives of CMC assessment. Sponsors are expected to provide a thorough description of the entire manufacturing process, from cell line development through upstream and downstream processing to formulation and filling operations. Regulatory authorities look for evidence that the process is well-characterized and capable of delivering products of consistent quality across multiple batches. Process validation studies must establish reproducibility and control, and all significant sources of variability must be identified and managed through appropriate control strategies.

The identification and control of critical quality attributes (CQAs) is another essential element of CMC requirements for biologics. CQAs physical, chemical, biological, or microbiological properties that must be maintained within defined limits to ensure product quality and clinical performance require thorough analytical characterization linking them to safety and efficacy outcomes. This characterization encompasses assessment of molecular structure, post-translational modifications, biological activity, stability profiles, and impurity levels. Regulatory authorities increasingly recommend advanced analytical methods and a risk-based approach to support a comprehensive understanding of both the product and its manufacturing process [33].

Figure 4. Key Components of CMC Evaluation for Biologics



Validation and comparability assessments are particularly important throughout the lifecycle of a biologic product. Manufacturing changes including scale-up, site transfers, equipment upgrades, and process optimizations are a practical reality during commercial production. Regulatory authorities require sponsors to demonstrate through comparability studies that post-change products remain equivalent to pre-change versions in terms of quality, safety, and efficacy. Depending on the nature and significance of the change, these evaluations may be anchored in analytical and functional data, or they may also incorporate nonclinical or clinical studies.

GMP compliance and manufacturing oversight are integral to regulatory decision-making for biologics. All major agencies conduct GMP inspections of manufacturing facilities both during the approval process and throughout the product's commercial lifecycle. Inspection outcomes can directly influence market authorization decisions and approval timelines. Reflecting the global nature of biologics supply chains, regulatory authorities are increasingly collaborating through mutual recognition arrangements and information-sharing mechanisms to improve inspection efficiency while maintaining rigorous quality standards [34].

Table 4. Comparison of CMC and Manufacturing Requirements for Biologics

CMC Element	FDA	EMA	PMDA	CDSCO	Reference
Process validation	Mandatory, lifecycle-based	Mandatory	Mandatory	Mandatory	**35**
Critical Quality Attributes (CQAs)	Strong emphasis	Strong emphasis	Strong emphasis	Increasing emphasis	**36**
Analytical characterization	Extensive orthogonal methods	Extensive	Extensive	Extensive	**37**
Comparability studies	Required for post-approval changes	Required	Required	Required	**36,38**
Quality by Design (QbD)	Encouraged	Encouraged	Encouraged	Gradually adopted	**38**
Lifecycle management	Change management protocols	Variations system	Partial change approvals	Change approval process	**39**
GMP inspection approach	Risk-based	Risk-based	Risk-based	Risk-based	**39**
Reliance on foreign inspections	Partial	Mutual recognition	Limited	Emerging	**39**

5. Nonclinical and Clinical Evidence Expectations

The FDA, EMA, PMDA, and CDSCO all apply a systematic, risk-based approach to evaluating nonclinical and clinical evidence for biologic products. This approach aims to generate sufficient data to establish the safety and efficacy of biologics while avoiding unnecessary duplication of studies where scientific rationale is strong. In view of the complexity of these molecules and their often well-defined mechanisms of action, regulatory authorities emphasize tailored development programs that integrate analytical, nonclinical, and clinical data in a scientifically justified manner.

At the nonclinical level, agencies look for pharmacology and toxicology studies that are relevant to the target biology and mechanism of action of the biologic being evaluated. Both in vitro and in vivo studies are used to establish proof of concept, characterize biological activity, and identify potential safety concerns. Where a biologic has a well-defined target and mechanism of action and is supported by robust analytical and functional characterization, regulatory agencies may accept a more focused nonclinical data package. This flexibility reflects an understanding that traditional animal models may have limited relevance for some biologics, particularly those with species-specific pharmacological activity [40].

Clinical development programs for biologics typically follow a sequential structure, beginning with early-phase studies assessing pharmacokinetics, pharmacodynamics, safety, and tolerability, and progressing to confirmatory trials designed to establish efficacy in the target patient population. When the evidence strongly supports a predictable relationship between a biologic's structure, mechanism of action, and clinical outcomes, regulatory agencies may permit a streamlined clinical program. Such reductions must, however, be supported by thorough analytical characterization and corroborating nonclinical data, and must not compromise patient safety [41

Figure 5. Evidence Framework for Nonclinical and Clinical Evaluation of Biologi



For all biologics, a systematic assessment of immunogenicity is a mandatory component of clinical evaluation. Since biologic products are protein-based and carry the potential to trigger immune responses, regulators require structured evaluation of anti-drug antibody formation and its possible effects on safety, pharmacokinetics, and therapeutic efficacy. Immunogenicity assessment is conducted throughout clinical development and typically continues into the post-marketing phase. Differences in assay design, patient populations, and treatment duration are carefully considered in interpreting immunogenicity findings to ensure clinically meaningful conclusions [42].

6. Expedited and Special Approval Pathways

To address unmet medical needs and facilitate earlier patient access to novel biologics, major regulatory agencies have developed a range of accelerated and specialized approval mechanisms. These pathways are particularly important for products targeting serious or life-threatening conditions, rare diseases, or disease areas where no adequate therapeutic alternatives currently exist. While the overarching goal is shared across jurisdictions, the specific structure, eligibility criteria, and regulatory maturity of accelerated pathways vary considerably.

In the United States, the FDA offers several distinct programs designed to expedite the development and review of biologics. Accelerated Approval allows initial authorization based on surrogate or intermediate clinical endpoints that are reasonably likely to predict clinical benefit, subject to the requirement to complete confirmatory post-marketing studies. For biologics offering a substantial improvement over existing therapies, Breakthrough Therapy Designation provides intensive regulatory guidance and strong organizational commitment from the FDA. The Regenerative Medicine Advanced Therapy (RMAT) designation supports the development of cell and gene therapies and other advanced biologics through enhanced FDA interaction and the potential for expedited review. Together, these programs reflect the FDA's well-developed framework for regulatory flexibility in addressing serious unmet needs [43].

Within the European Union, the EMA has established the PRIME (PRIority MEdicines) scheme and Conditional Marketing Authorization as its principal accelerated mechanisms. PRIME provides early and proactive regulatory support for medicines with the potential to address unmet medical needs, facilitating optimized development plans and faster scientific evaluation. Conditional Marketing Authorization permits approval of biologics based on less complete clinical evidence when the benefit-risk profile is favorable and an unmet need exists, with the requirement to provide comprehensive confirmatory data post-approval. These mechanisms enable timely patient access while maintaining appropriate regulatory oversight [44].

In Japan, the PMDA and MHLW administer accelerated review mechanisms including the Sakigake designation, which prioritizes review of innovative treatments that were first developed in Japan. For regenerative and cell-based therapies, Japan has developed conditional and time-limited approval frameworks that allow early market entry on the basis of preliminary evidence, paired with stringent requirements for post-marketing data collection. These frameworks reflect Japan's forward-looking regulatory stance on advanced biologic technologies and its commitment to making innovative therapies available to patients without compromising safety standards [45].

In India, expedited pathways for biologics under CDSCO are less formally established than in the US, EU, or Japan. While CDSCO has introduced provisions for priority review in situations involving unmet medical needs, public health emergencies, or matters of national importance, a single well-defined and structured fast-track system comparable to those in other jurisdictions does not yet fully exist. India's regulatory framework is

progressively moving toward more structured expedited pathways, with growing use of conditional approvals and increasing reliance on international regulatory expertise though further development in regulatory clarity and standardization remains an area for ongoing improvement [46].

Figure 6. Expedited and Special Approval Pathways for Biologics



7. Biosimilar and Similar Biologics

Biosimilars referred to in some jurisdictions as "similar biologics" are a vital strategy for broadening patient access to biologic treatments while upholding rigorous standards of quality, safety, and efficacy. The regulatory evaluation of biosimilars worldwide is anchored in the principle of comparability, which requires demonstration that the proposed product is highly similar to an already-approved reference biologic with no clinically meaningful differences in safety, purity, or potency. Rather than requiring entirely independent development programs, this comparability-driven approach emphasizes thorough analytical characterization and a stepwise accumulation of evidence.

In the United States, biosimilars are regulated by the FDA under the Biologics Price Competition and Innovation Act (BPCIA). The FDA distinguishes between products that are biosimilar to the reference biologic and those that are designated as interchangeable with it. Demonstrating biosimilarity requires showing high analytical similarity with no clinically significant differences, while achieving an interchangeability designation requires additional evidence that the biosimilar produces the same clinical outcome in any given patient and that switching between the biosimilar and the reference product does not increase risk. This distinction has meaningful implications for pharmacy-level substitution practices and underscores the FDA's careful, evidence-based approach to biosimilar use. Robust pharmacovigilance and post-marketing surveillance are also strongly emphasized to track long-term safety and immunogenicity [47].

The EMA has established itself as a global leader in biosimilar regulation, having authorized a substantial number of biosimilars through its centralized review process since the framework was first put in place. This centralized evaluation ensures a single, consistent scientific assessment applicable to all EU member states. The EMA's biosimilar methodology is grounded in rigorous analytical comparability, supported by tailored nonclinical and clinical studies including pharmacokinetic, pharmacodynamic, and immunogenicity evaluations. Notably, interchangeability and automatic substitution decisions are not determined at the EU level by the EMA; rather, these are left to individual member states. This separation between scientific evaluation and substitution policy allows national flexibility while maintaining harmonized scientific standards throughout Europe [48].

In Japan, the PMDA regulates biosimilars within a framework closely aligned with WHO and ICH guidance. The PMDA applies a rigorous, comparability-driven approach requiring comprehensive analytical similarity data supported by clinical studies designed to confirm equivalent immunogenicity, safety, and efficacy. Local clinical data or strong scientific justification for extrapolation from international studies is frequently expected. Japan's significant post-marketing surveillance obligations reflect the country's strong commitment to long-term safety monitoring and the generation of real-world evidence for biosimilar products [49].

In India, CDSCO regulates biosimilars as "similar biologics" under the "Guidelines on Similar Biologics," which have been updated on several occasions to improve alignment with international standards. The

Indian regulatory framework requires comparative quality studies, nonclinical evaluation, and clinical trials to establish similarity with the reference biologic. Earlier versions of the guidelines required relatively larger clinical data packages; subsequent revisions have placed greater emphasis on analytical characterization and risk-based reduction of clinical studies where substantial similarity is robustly demonstrated. The framework continues to develop, reflecting India's dual imperatives of protecting public health and nurturing its growing domestic biologics manufacturing sector [50].

Despite broad international consensus around comparability principles, significant differences remain among regulatory jurisdictions in areas such as clinical evidence requirements, interchangeability classifications, indication extrapolation policies, and substitution practices. These differences present both strategic challenges for sponsors pursuing multi-regional biosimilar approvals and opportunities for further regulatory convergence. Ongoing collaboration through international forums such as the WHO and ICH will be essential to strengthening alignment while honoring the legitimate healthcare context of individual regions.

Table 5. Biosimilar Regulatory Frameworks Across FDA, EMA, PMDA, and CDSCO

Regulatory Aspect	FDA	EMA	PMDA	CDSCO	Reference
Legal terminology	Biosimilar / Interchangeable	Biosimilar	Biosimilar	Similar Biologic	**51**
Reference product	US-licensed biologic	EU-authorized biologic	Japan-approved biologic	Indian or foreign reference	**52**
Analytical comparability	Extensive, stepwise	Extensive	Extensive	Extensive	**52**
Clinical data requirements	Reduced, risk-based	Reduced	Often required	Historically extensive	**53**
Interchangeability	Separate legal designation	Member-state decision	No formal category	Not formally defined	**54**
Indication extrapolation	Permitted with justification	Permitted	Cautious	Permitted	**53,54**
Post-marketing surveillance	Mandatory	Mandatory	Mandatory	Mandatory	**54,55**

8. Post-Approval Obligations and Pharmacovigilance

Pharmacovigilance and post-approval obligations constitute essential pillars of the regulatory lifecycle management of biologic medicines. Unlike small-molecule drugs, biologics are characterized by complex molecular architectures, biological variability, and the capacity to elicit immunological responses effects that may only become fully apparent after exposure in large and diverse patient populations. For these reasons, all major regulatory authorities, including the FDA, EMA, PMDA, and CDSCO, place substantial emphasis on ongoing safety monitoring and continuous benefit-risk evaluation following market authorization.

A core requirement across jurisdictions is the development and maintenance of comprehensive risk management plans (RMPs) or equivalent frameworks, such as Risk Evaluation and Mitigation Strategies (REMS) in the United States. These plans serve to systematically identify known and potential risks associated with a biologic, define strategies for risk minimization, and establish procedures for ongoing safety monitoring. Risk management plans are treated as living documents that must be updated in response to emerging safety information, changes in clinical use, or advances in scientific knowledge. The scope and complexity of risk management activities typically reflect the novelty of the product, its mechanism of action, and its clinical risk profile [56].

Periodic safety reporting is another fundamental component of post-marketing oversight for biologics. Marketing authorization holders are required to submit Periodic Safety Update Reports (PSURs) or equivalent documents at defined intervals, providing cumulative analyses of adverse events, significant adverse reactions, and safety signals observed in real-world use. These reports routinely include updated benefit-risk assessments that account for long-term exposure data, new indications, and broader patient populations. Regulatory authorities use PSURs to determine whether further regulatory action is warranted, such as requesting additional studies, updating prescribing information, or implementing new risk-minimization measures.

Long-term immunogenicity monitoring is a critical and indispensable component of pharmacovigilance for biologics. Since biologic products are protein-based and may trigger immune responses, regulators require ongoing monitoring of anti-drug antibody formation and its clinical consequences, including loss of efficacy, hypersensitivity reactions, and immune-mediated adverse effects. Post-approval immunogenicity data frequently provides insights not fully captured in pre-authorization clinical studies, particularly where pre-marketing sample sizes were limited or follow-up periods were short. Regulatory authorities therefore maintain close attention to immunogenicity trends and may require additional studies or enhanced surveillance where safety concerns emerge.

Post-marketing requirements are more stringent and legally binding for biologics approved through conditional, accelerated, or expedited pathways. Such approvals are often granted on the basis of limited clinical datasets, surrogate endpoints, or early indications of efficacy in serious or life-threatening conditions. In these circumstances, regulatory agencies require completion of confirmatory post-marketing clinical studies to establish definitive clinical benefit, better characterize long-term safety, and refine the overall benefit-risk profile. Adherence to agreed timelines for completing these studies is a critical condition of market authorization maintenance; failure to comply may result in regulatory consequences including indication restrictions or license withdrawal.

Post-approval regulatory oversight also encompasses continuous manufacturing and quality surveillance. Regulatory agencies conduct routine and unannounced GMP inspections to verify ongoing compliance with approved manufacturing processes and quality control procedures. Any post-approval changes to manufacturing sites, processes, or raw materials must be reported and justified with supporting comparability data to demonstrate that product quality remains unaffected [57].

9. Areas of Regulatory Convergence

Over the past decade, regulatory frameworks governing biologic medicines have exhibited growing convergence among major international agencies, driven by advances in regulatory science, international cooperation, and the globalization of pharmaceutical research. Despite operating within distinct legal and healthcare environments, agencies including the FDA, EMA, PMDA, and CDSCO have progressively aligned many of their scientific principles and regulatory expectations, contributing to more efficient development processes and more consistent standards of quality, safety, and efficacy across borders.

A significant area of convergence is the broad adoption of guidelines developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH quality, safety, and efficacy guidelines including those addressing biologics-specific issues such as stability, quality-by-design, nonclinical safety, and clinical evaluation have become foundational references across many regulatory systems. By establishing a shared scientific vocabulary and common technical standards, these guidelines have reduced variation in regulatory submissions and evaluations. For emerging regulatory systems in particular, alignment with ICH principles has been especially important in strengthening oversight capabilities and supporting participation in global development programs [58].

Growing acceptance of data from international clinical trials represents another meaningful area of convergence. Regulatory authorities are increasingly recognizing the value of global clinical studies conducted in accordance with Good Clinical Practice (GCP) standards, provided that the study design, patient population, and clinical outcomes are scientifically applicable to the local healthcare setting. Although some agencies continue to request bridging data or local studies in specific circumstances, the overall direction is clearly toward greater reliance on global evidence for regulatory decision-making. This shift has accelerated development timelines, reduced duplication in clinical trial activity, and improved the overall efficiency of international biologics development [59].

Advances in analytical technology have also promoted convergence toward a stronger emphasis on analytical and functional characterization in biologics evaluation. Regulatory agencies are placing increasing trust in modern analytical tools capable of characterizing molecular structure, biological activity, and key quality attributes in detail. This has enabled a more science-driven, risk-based regulatory approach, in which rigorous analytical evidence can justify streamlined nonclinical and clinical requirements. The shared recognition that comprehensive product and process knowledge is central to sound biologics regulation reflects an area of deep scientific alignment across jurisdictions [60].

10. Areas of Regulatory Divergence

Despite considerable progress toward harmonization, meaningful areas of regulatory divergence persist among the major international agencies overseeing biologic products. These differences reflect variations in regulatory maturity, legal frameworks, healthcare system structures, and public health priorities rather than fundamental disagreements in scientific principles. Understanding these divergences is important both for sponsors designing global development strategies and for policymakers seeking to balance regulatory flexibility with robust patient protection.

Among the most significant areas of divergence are policies governing interchangeability and substitution, particularly for biosimilars. The definition and practical operationalization of interchangeability and the extent of discretion granted to pharmacists for automatic product substitution vary considerably across jurisdictions. In the United States, for example, the FDA maintains a distinct regulatory designation for interchangeable biosimilars, requiring evidence beyond standard biosimilarity to support switching. By contrast, the EMA does not evaluate interchangeability at the EU level, leaving substitution decisions to the discretion of individual member states. Other jurisdictions apply their own approaches based on national healthcare legislation, contributing to regional differences in clinical practice and market dynamics [61].

The scope and conditions of accelerated and special approval pathways represent another source of divergence. While all major agencies offer mechanisms to expedite access to biologics addressing unmet medical needs, the eligibility criteria, evidentiary standards, and post-approval obligations associated with these pathways differ substantially. The FDA, EMA, and PMDA each operate well-established and clearly defined accelerated pathways, while newer or emerging regulatory systems may apply more flexible or case-by-case approaches. These differences can result in

inconsistent patient access timelines and create additional complexity for sponsors seeking simultaneous multi-regional approvals [62].

Divergence is also evident in the degree to which regulatory agencies rely on or formally recognize international approvals. Some authorities are increasingly willing to leverage assessments conducted by recognized reference agencies to streamline their own reviews, while others maintain largely independent evaluation systems and require comprehensive local assessment regardless of prior approvals elsewhere. These differences in reliance policies affect submission strategies, review timelines, and resource allocation for sponsors engaged in global biologics development.

Finally, local legal and healthcare system factors play a significant role in shaping regulatory divergence. National legislation, reimbursement policies, pharmacovigilance infrastructure, and prevailing clinical practice patterns all influence regulatory decision-making and post-approval requirements. Even where scientific standards are broadly aligned, these contextual factors may necessitate region-specific data packages, risk management strategies, or labeling provisions [63].

Figure 7. Global Convergence and Divergence in Biologics Regulation



11. Harmonization Challenges

Despite meaningful progress in aligning biologics regulations globally, full regulatory harmonization across regions continues to face a number of persistent and substantive obstacles. These challenges stem not primarily from scientific disagreement, but from differences in regulatory maturity, institutional capacity, public health priorities, and national legislative requirements. Addressing these barriers is necessary to achieve more efficient global development pathways while preserving the high safety standards that patients rightly expect [64].

One of the most fundamental barriers to harmonization is the variation in the legal and regulatory frameworks governing pharmaceutical products across jurisdictions. Regulatory agencies operate within national or regional laws that define approval procedures, enforcement powers, and decision-making authority. These legislative frameworks reflect country-specific political considerations, healthcare system requirements, and public health priorities. As a result, even where scientific standards are broadly aligned, implementation in areas such as accelerated approvals, post-marketing obligations, labeling requirements, and enforcement mechanisms can differ substantially. These legal constraints place inherent limits on the degree to which regulators can fully accept or build upon decisions made by foreign authorities [65].

Disparities in regulatory capacity between regions represent another significant challenge. Established agencies such as the FDA, EMA, and PMDA typically possess sophisticated analytical infrastructure, deep scientific expertise, and well-developed pharmacovigilance and inspection systems. Regulatory bodies in developing or resource-constrained settings, by contrast, may face limitations in access to advanced technologies, skilled personnel, and technical capabilities. These disparities can affect the comprehensiveness and speed of regulatory assessment, the ability to evaluate complex biologic products, and the credibility of reliance or mutual recognition arrangements all of which can slow the pace of harmonization.

Limited mutual recognition of GMP inspections, post-approval modifications, and pharmacovigilance findings further complicates global alignment. Despite cooperative efforts and bilateral information-sharing agreements, full bilateral recognition of manufacturing inspections and regulatory actions remains the exception rather than the rule. Regulatory bodies frequently conduct independent assessments to meet domestic legal accountability requirements, even where another authority has already completed a thorough evaluation. This duplication not only increases the regulatory burden on sponsors but also delays international approvals and diverts limited regulatory resources that

could be more effectively deployed through coordinated oversight [66].

12. Future Outlook

The global regulatory landscape for biologics is expected to move progressively toward greater scientific alignment and procedural efficiency, driven by expanded acceptance of international standards and more robust collaborative frameworks. Regulatory agencies are anticipated to increase their reliance on WHO and ICH guidelines to ensure consistent evaluation of safety, quality, and efficacy across regions. Broader application of ICH quality and safety standards will further harmonize expectations for manufacturing controls, comparability assessments, and biologics lifecycle management across jurisdictions.

At the same time, regulatory agencies are increasingly recognizing the value of real-world evidence (RWE) generated through patient registries, electronic health records, and post-marketing surveillance systems. The systematic integration of RWE into regulatory decision-making is anticipated to support accelerated approvals, indication expansions, and the fulfillment of post-approval commitments particularly for biologics addressing rare diseases, oncology indications, and other unmet medical needs. This development reflects a growing consensus that evidence generated beyond the controlled clinical trial setting has a legitimate and important role in regulatory assessment.

Enhanced regulatory collaboration and reliance mechanisms are expected to play an increasingly important role in accelerating global biologics development. Collaborative review initiatives, work-sharing programs, and mutual reliance on GMP inspections and scientific evaluations offer meaningful opportunities to reduce duplication and shorten approval timelines. This form of collaboration is especially valuable in regions where regulatory expertise is still developing, enabling more timely patient access to biologic medicines. Simultaneously, regulatory frameworks will continue to adapt to meet the demands of emerging biologic modalities such as cell and gene therapies and other advanced therapeutic products. These modalities raise distinct challenges in areas including long-term safety monitoring, personalized treatment approaches, and manufacturing complexity. Regulators are expected to develop more sophisticated pharmacovigilance systems, risk-based oversight mechanisms, and adaptive approval pathways in response. Collectively, these developments suggest a future regulatory environment that is more scientifically rigorous, internationally coordinated, and better equipped to support innovation in biologic therapies.

13. Conclusion

Biologics represent one of the most significant advances in modern medicine, offering targeted and effective treatment options for a wide spectrum of serious and chronic conditions. Their inherent complexity, biological variability, and sensitivity to manufacturing changes necessitate rigorous and specialized regulatory oversight throughout the product lifecycle. As this comparative analysis of regulatory pathways across the FDA, EMA, PMDA, and CDSCO has shown, the core scientific principles governing biologics evaluation quality, safety, and efficacy are broadly consistent across jurisdictions, yet notable differences persist in submission procedures, evidentiary standards, accelerated approval mechanisms, biosimilar interchangeability policies, and post-approval obligations. These differences continue to shape global development strategies and approval timelines.

At the same time, the direction of travel is clearly toward greater regulatory convergence, underpinned by the growing adoption of ICH and WHO standards, increasing acceptance of global clinical evidence, and advances in analytical characterization. Sustained international cooperation, regulatory reliance mechanisms, and capacity-building efforts will be essential to resolving remaining differences and addressing ongoing harmonization challenges. As biologic innovation advances into cutting-edge modalities such as cell and gene therapies, regulatory frameworks must remain both flexible and scientifically grounded. Strengthening international collaboration while respecting the legitimate context of regional regulatory systems will be critical to ensuring that patients worldwide have timely access to safe, effective, and high-quality biologic treatments.

References

1. McGonigle P. How biologics have changed the drug discovery landscape. Annual review of pharmacology and toxicology. 2025 Jan 23;65(1):29-46.
2. Liu XR, Zhang MM, Gross ML. Mass spectrometry-based protein foot printing for higher-order structure analysis: fundamentals and applications. Chemical reviews. 2020 Apr 22;120(10):4355-454.
3. Sarkis M, Bernardi A, Shah N, Papathanasiou MM. Emerging challenges and opportunities in pharmaceutical manufacturing and distribution. Processes. 2021 Mar 3;9(3):457.
4. Shokry RF. Forging certainty: A novel framework for the specification of combination products. Journal of Pharmaceutical Sciences. 2025 Dec 24:104145.
5. Waldron JL, Schworer SA, Kwan M. Hypersensitivity and immune-related adverse events in biologic therapy. Clinical Reviews in Allergy & Immunology. 2022 Jun;62(3):413-31.
6. Geigert J. Demonstrating Product Comparability After Process Changes. In The Challenge of CMC Regulatory Compliance for Biopharmaceuticals 2019 May 9 (pp. 381-412). Cham: Springer International Publishing.
7. Chirmule N. Regulatory Strategy. In Approved: The Life Cycle of Drug Development 2025 Apr 30 (pp. 549-568). Cham: Springer Nature Switzerland.
8. Car E, Barbier L, Huys I, Simoens S, Vulto AG. Evolving global regulatory landscape for approval of biosimilars: current challenges and opportunities for convergence. Expert Opinion on Biological Therapy. 2025 Jun 3;25(6):649-68.

9. Cordeiro MAC, Vitorino C, Sinogas C, Sousa JJ. A regulatory perspective on biosimilar medicines. Pharmaceutics. 2024;16(3):321.
10. Müller MM. Post-translational modifications of protein backbones: unique functions, mechanisms, and challenges. Biochemistry. 2018 Jan 16;57(2):177-85.
11. Odum J, Flickinger MC, editors. Process architecture in biomanufacturing facility design. John Wiley & Sons; 2018 Jan 26.
12. Mockus L, Peterson JJ, Lainez JM, Reklaitis GV. Batch-to-batch variation: a key component for modeling chemical manufacturing processes. Organic Process Research & Development. 2015 Aug 21;19(8):908-14.
13. Krishna M. Product-related factors and immunogenicity of biotherapeutics. Journal of Pharmaceutical Innovation. 2020 Jun;15(2):219-31.
14. Oberweis CV, Marchal JA, López-Ruiz E, Gálvez-Martín P. A worldwide overview of regulatory frameworks for tissue-based products. Tissue Engineering Part B: Reviews. 2020 Apr 1;26(2):181-96.
15. Pollock JR, Anderson ST, Moore ML, Smith JF. The food and drug administration. Translational Orthopedics. 2024 Jan 1:375-9.
16. Miyazawa M, Tanaka M, Tanaka Y, Terashima R, Ezura M, Miyazawa H, Ikuma M, Tomita Y. Concordance between pharmaceuticals and medical devices agency review and ministry of health, labour and welfare decision among new drug applications in Japan. Clinical Pharmacology & Therapeutics. 2025 Feb;117(2):544-53.
17. Maurya SK, Shukla V, Kaushik P, Kanti SY, Bansal A. Regulatory aspects for Biologic product licensing in India. International Journal of Drug Regulatory Affairs (IJDRA). 2019;7(1):1-5.
18. Avhad VR, Patil SB. A comparison of US, Europe, Japan and India biosimilar regulation. Int J Drug Regul Aff. 2025;13(1):34–9.
19. Shorthose S. Guide to EU and UK pharmaceutical regulatory law.
20. Rudrapal M, Khairnar SJ, Hussain N, Sarwa KK. Biosimilars: present status, challenges and future prospects. Asian Journal of Science and Technology. 2020;11(12):11376-81.
21. Dhandia D, Jain S, Shukla VK, Sharma N, Yadav P, Arora S. International Council for Harmonization: Reception to Implementation. InUnderstanding Pharmaceutical Standards and Regulations 2025 (pp. 240-264). Routledge.
22. Punia A, Malhotra H. International regulatory processes and policies for innovator biologics, biosimilars, and biobetters. Biologics, Biosimilars, and biobetters: An introduction for pharmacists, physicians, and other health practitioners. 2020 Dec 30:159-76.
23. Cácananta OV. FDA and Regulation of Biologics. InNavigating the FDA Regulatory Processes 2025 Jan 31 (pp. 88-100). CRC Press.
24. Gjeorgiev B, Miceva D, Karpicarov D, Apostolova P, Bogevski K, Arev M, Gjorgjeska B. A comparative study of the procedures for medicine approval in the European Union and the United States. Arhiv za farmaciju. 2025 Feb 17;75(2):101-13.
25. Iwamoto S, Cavanaugh K, Malone M, Lottes A, Thatcher R, Kumar K, Rowland S, Fearnot N, Uchida T, Iwaishi C, Senshu K. Global medical device clinical trials involving both the United States and Japan: Key considerations for development, regulatory approval, and conduct. Cardiovascular Revascularization Medicine. 2023 Jul 1;52:67-74.
26. Trivedi D, Thummar K, Maheriya B, Chauhan S. Navigating the Regulatory Landscape: Key Transformations in India's Drug & Clinical Trials Regulations-A Comparative Analysis with the USA & Europe. ADVANCES IN PHARMACOLOGY. 2025;13(2):204-13.
27. John Gerard S, Ramachandran V. Navigating regulatory complexities in biosimilar approvals: a comparative analysis of FDA, EMA and CDSCO guidelines. Recent Adv Drug Deliv Formul. 2025;19:1–15.
28. Wang J, Chow SC. Global regulatory approval pathways for biologics and biosimilars. Ther Innov Regul Sci. 2024;58(2):345–56.
29. Lavertu S, Weimer DL. Federal advisory committees, policy expertise, and the approval of drugs and medical devices at the FDA. Journal of Public Administration Research and Theory. 2011 Apr 1;21(2):211-37.
30. Karasawa H, Mizoguchi H, Choi B, Hsieh CL, Miyano M, Moriya Y, Muthusamy S, Takakura K, Suzuki K, Tsurumaki Y, Watanabe T. Regulatory insights on advanced CAR-T cell products, AAV-based Gene therapies, and medical care/practice in cell and Gene therapies: Report from the 6th Asia partnership conference of regenerative medicine-April 20, 2023. Regenerative Therapy. 2024 Jun 1;26:967-80.
31. Richesson RL, Krischer J. Data standards in clinical research: gaps, overlaps, challenges and future directions. Journal of the American Medical Informatics Association. 2007 Nov 1;14(6):687-96.
32. Kabir M, Rana MR, Debnath A. The role of quality assurance in accelerating pharmaceutical research and development: strategies for ensuring regulatory compliance and product integrity. Journal of Angiotherapy. 2024 Dec 8;8(12):1-1.
33. Kendrick BS, Gabrielson JP, Hunt D, Christie M, Bowen S, Vessely C, Rogers RS, Cleveland C, Maluf K, Roach S, Ritter N. Quality risk management and data integrity in R&D laboratories supporting CMC lifecycle of biological products. Journal of Pharmaceutical Sciences. 2024 Nov 1;113(11):3123-36.
34. Radhakrishnan P, SP D, GNK G. Comprehensive Analysis of FDA Form 483 Issued for Biologics from 2010 to 2025: Identifying Trends and Areas of Concern. Journal of Pharmaceutical Innovation. 2026 Apr;21(2):120.
35. Sayeed-Desta N, Pazhayattil A, Ingram M. Lifecycle-based process validation emphasizes the

need for continued process verification. Pharmaceutical Technology. 2018 Aug 1;2018(3):s22-5.
36. Schofield T, Robbins D, Miró-Quesada G. Critical quality attributes, specifications, and control strategy. InQuality by Design for Biopharmaceutical Drug Product Development 2015 Apr 2 (pp. 511-535). New York, NY: Springer New York.
37. Kerschen G, Golinval JC, Vakakis AF, Bergman LA. The method of proper orthogonal decomposition for dynamical characterization and order reduction of mechanical systems: an overview. Nonlinear dynamics. 2005 Aug;41(1):147-69.
38. Kajiwara E, Kamizato H, Shikano M. Impact of quality by design development on the review period of new drug approval and product quality in Japan. Therapeutic Innovation & Regulatory Science. 2020 Sep;54(5):1192-8.
39. Gottipati VK. Mastering Quality Assurance in Pharma: A Comprehensive Guide to cGMP, Risk Management 2025. YASHITA PRAKASHAN PRIVATE LIMITED;.
40. Vargas HM, Amouzadeh HR, Engwall MJ. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. Expert opinion on drug safety. 2013 Jan 1;12(1):91-102.
41. Barde P, Barde M. Perspective on Clinical Trials: What Researchers Need to Know. InApproved: The Life Cycle of Drug Development 2025 Apr 30 (pp. 395-441). Cham: Springer Nature Switzerland.
42. Pineda C, Castañeda Hernández G, Jacobs IA, Alvarez DF, Carini C. Assessing the immunogenicity of biopharmaceuticals. BioDrugs. 2016 Jun;30(3):195-206.
43. Kinch MS. An overview of FDA-approved biologics medicines. Drug discovery today. 2015 Apr 1;20(4):393-8.
44. Antoñanzas F, Juárez-Castelló CA, Rodríguez-Ibeas R. EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data. The European Journal of Health Economics. 2018 Sep;19(7):905-7.
45. Nagai S. Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan. International journal of molecular sciences. 2019 Aug 3;20(15):3801.
46. Patil N, Ranjan A, Gaurav, Mukherjee D, Panda BK, Diksha, Komal, Narang RK, Singh A. Navigating biosimilar regulatory pathways in emerging markets: Insights from BRICS nations. Applied Drug Research, Clinical Trials and Regulatory Affairs. 2024 Nov 6.
47. Koyfman BH. Biosimilarity and interchangeability in the biologics Price competition and innovation act of 2009 and FDA's 2012 draft guidance for industry. Biotechnology law report. 2013 Aug 1;32(4):238-51.
48. Gherghescu I, Delgado-Charro MB. The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. Pharmaceutics. 2020 Dec 31;13(1):48.
49. Bhunia SS, Kaushal N, Kumar R. Regulatory Landscape of the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Pharmaceutical Regulatory Affairs. 2026:149-73.
50. Rathore AS, Joshi S, Bhargava A, Nupur N. Development and Commercialization of Biosimilars in India: Current Regulatory and Clinical Experience. InBiosimilars: Regulatory, Clinical, and Biopharmaceutical Development 2018 Dec 14 (pp. 653-674). Cham: Springer International Publishing.
51. Park JP, Jung B, Park HK, Shin D, Jung JA, Ghil J, Han J, Kim KA, Woollett GR. Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One: JP Park et al. BioDrugs. 2022 Jul;36(4):431-6.
52. Sharma A. Biosimilar Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases: A Comprehensive Review. Journal of Retina-Vitreous/Retina Vitreus. 2025 Oct 1;34(4).
53. Barnes B, Stansbury N, Brown D, Garson L, Gerard G, Piccoli N, Jendrasek D, May N, Castillo V, Adelfio A, Ramirez N. Risk-based monitoring in clinical trials: past, present, and future. Therapeutic innovation & regulatory science. 2021 Jul;55(4):899-906.
54. Drnovšek K. Comparative View on the Divergence of Structure and Substance of Judgements. InDiversity of Enforcement Titles in the EU 2023 Dec 31 (pp. 111-151). Cham: Springer International Publishing.
55. Viarengo I. APPLICABLE LAW: CHOICE OF LAW. InEU Cross-Border Succession Law 2022 Jun 10 (pp. 132-149). Edward Elgar Publishing.
56. Butler D, Vucic K, Straus S, Cupelli A, Micallef B, Serracino-Inglott A, Borg JJ. Regulatory experience of handling risk management plans (RMPs) for medicinal products in the EU. Expert Opinion on Drug Safety. 2021 Jul 3;20(7):815-26.
57. Lawrence XY, Woodcock J. FDA pharmaceutical quality oversight. International journal of pharmaceutics. 2015 Aug 1;491(1-2):2-7.
58. Dangy-Caye A, Mousset A, Kermad A, Bouché-Bazerolle L, Bujar M, De Lucia ML, McAuslane N, Lumsden R. Harmonizing health: a global analysis of pharmaceutical regulatory activities by international regulatory organizations. Frontiers in Medicine. 2025 Sep 23;12:1636269.
59. Vijayananthan A, Nawawi O. The importance of Good Clinical Practice guidelines and its role in clinical trials. Biomedical imaging and intervention journal. 2008 Jan 1;4(1):e5.
60. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature reviews Drug discovery. 2012 Jul;11(7):527-40.
61. Afzali A, Furtner D, Melsheimer R, Molloy PJ. The automatic substitution of biosimilars: definitions of interchangeability are not interchangeable. Advances in Therapy. 2021 May;38(5):2077-93.
62. Nagai S, Ozawa K. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.

International journal of hematology. 2016 Jul;104(1):73-84.
63. Espina C, Ritchie D, Feliu A, Canelo-Aybar C, D'Souza E, Mitrou PN, Carvalho AL, Schüz J, Zeeb H. Developing evidence-based cancer prevention recommendations: methodology of the world code against cancer framework to create region-specific codes. International Journal of Cancer. 2026 Jan 1;158(1):9-18.
64. Mukonzo JK, Ndagije HB, Sabblah GT, Mathenge W, Price DA, Grasela TH. Expanding regulatory science: Regulatory complementarity and reliance. Clinical and Translational Science. 2024 Jan;17(1):e13683.
65. Umaru OT, Adeyemi AS, Aderonmu O, Bhangu BS, Dhaliwal HS, Lim H, Aremu TO. Global pharmaceutical regulation: Comparative frameworks and operations. Pharmacy. 2026 Mar 18;14(2):50.
66. Pagadala MV. ONE MEDICINE, MANY RULES: GLOBAL HARMONIZATION AND REGULATORY FRAGMENTATION IN DRUG APPROVALS. World Journal of Pharmaceutical Sciences. 2026 Apr 29.